News Summary:
MILFORD, Mass., Dec. 19, 2023 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced it has been awarded the prestigious Accountability, Consistency, and Transparency (ACT) label for its Waters Xevo TQ Absolute system from My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research. The Xevo TQ Absolute system is a compact benchtop tandem quadrupole mass spectrometer with industry-leading performance and design features that make it one of the most sustainable analytical systems in its class.ii
"The ACT label on Waters Xevo TQ Absolute system signifies it is more than just a product – it is a commitment to a sustainable future for scientific research and laboratory best practices that allows customers to achieve improved environmental sustainability and lower operational costs," said James Hallam, Vice President and General Manager, Testing & Lab Services, Waters Corporation. "As our company strives to leave the world better than we found it, the ACT label makes it easy for customers to make an environmentally conscious choice without having to sacrifice analytical performance and results."
The Xevo TQ Absolute system is one of the most sensitive benchtop mass spectrometers on the market, able to detect extremely low levels of per- and polyfluoroalkyl (PFAS) compounds. The industry has seen a surging demand for PFAS testing, especially with new regulations that will require lower limits for the presence of these "forever chemicals," particularly in food and drinking water.
The system boasts one of the smallest benchtop footprints of any high sensitivity mass spectrometer on the market and delivers a more sustainable solution in terms of its overall resource consumption. The Xevo TQ Absolute system uses approximately 50% less electricity and nitrogen and generates 50% less heat than most other instruments in its class.i Finding even more ways to reduce the system's environmental footprint, Waters builds the Xevo TQ Absolute system with components made from 20% recycled steel and ships each product in packaging that contains 40-60% recycled cardboard.
The Environmental Impact Factor (EIF) criteria, forming the basis for the ACT label, was crafted with insights from scientists, sustainability directors, procurement specialists, and manufacturers. By emphasizing Accountability, Consistency, and Transparency (ACT) around manufacturing, energy and water use, packaging, and end-of-life, ACT makes it easy to choose more sustainable products. The Waters Xevo TQ Absolute system earned the ACT label through a rigorous third-party verification process, highlighting Waters commitment to a sustainable mindset across multiple dimensions.
Additional Resources
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With approximately 8,000 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters and Xevo are trademarks of Waters Technologies Corporation.
Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
Mobile: +1.617.823.5555
i Based on a comparison of product specifications for the Sciex 7500, Sciex 6500, Agilent 6495D, and Thermo Scientific TSQ Altis.
ii Based on a comparison of the sensitivity and product specifications of currently available instruments on the market.
Last Trade: | US$357.77 |
Daily Change: | 13.06 3.79 |
Daily Volume: | 660,932 |
Market Cap: | US$21.240B |
November 07, 2024 November 01, 2024 October 10, 2024 October 08, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB